<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951753</url>
  </required_header>
  <id_info>
    <org_study_id>17091</org_study_id>
    <secondary_id>I8F-MC-GPGT</secondary_id>
    <secondary_id>2018-003343-37</secondary_id>
    <nct_id>NCT03951753</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study for participants with type 2 diabetes mellitus. The main purpose of this
      study is to learn more about how tirzepatide and placebo affect the body's ability to respond
      to blood sugar levels after a meal. The study will last up to 38 weeks, including a 28-week
      treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">April 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Total Clamp Disposition Index (cDI)</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Measured prior to standardized mixed-meal tolerance tests (sMMTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Postmeal Glucose</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Measured during sMMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>ISR0-120 will be determined from C-peptide concentrations using the deconvolution technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Concentration at Fasting</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>Measured prior to sMMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Concentration at Postmeal</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>Incremental AUC from time zero to 240 minutes after start of the meal [AUC0-240min]) during sMMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Food Intake During Ad Libitum Meal</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Ad libitum meal served buffet-style. Food intake will be recorded during a 45 minute period. The total amount of calories as well as the caloric breakdown (carbohydrates, protein, and fats) will be calculated from the respective nutritional information of the food items.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Semaglutide administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have T2DM for at least 6 months

          -  Treated with diet and exercise and stable dose(s) of metformin, with or without 1
             additional stable dose of oral antihyperglycemia medication other than metformin, 3
             months prior to study entry

          -  Have a hemoglobin A1c (HbA1c) value at screening of ≥7% and ≤ 9.5 % if on metformin
             only; or ≥6.5% and ≤9.0% if on metformin in combination with oral antihyperglycemia
             medications other than metformin

          -  Have a body mass index (BMI) between 25 and 45 kilograms per square meter (kg/m² )
             inclusive, at screening; are of stable weight (±5%) &gt;3 months prior to screening

        Exclusion Criteria:

          -  Have a history of proliferative retinopathy or maculopathy as determined by the
             investigator based on a recent (&lt;1.5 years) ophthalmologic examination

          -  Impaired renal estimated glomerular filtration rate (eGFR) &lt;45 milliliters per minute
             per 1.73 square meters (mL/min/1.73 m²) calculated by Chronic Kidney Disease
             Epidemiology Collaboration (CKD-EPI)

          -  Have a history or current cardiovascular, respiratory, hepatic, renal, GI,endocrine,
             hematological or neurological disorders capable of significantly altering the
             absorption, metabolism or elimination of drugs; of constituting a risk when taking the
             study drug; or of interfering with the interpretation of data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>49213140180</phone>
    </contact>
    <investigator>
      <last_name>Johannes de Vries</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>49 (0)6131 2162 700</phone>
    </contact>
    <investigator>
      <last_name>Leona Plum-Mörschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

